The Gross Law Firm has initiated a class action lawsuit against Intellia Therapeutics, alleging that the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency. The lawsuit claims Intellia failed to disclose the declining relevance of viral-based editing and subsequently halted the program, reducing workforce by 27% and causing stock price to drop from $12.02 to $10.20.